VIENNA, Austria, Nov. 03, 2022 (GLOBE NEWSWIRE) -- APEIRON Respiratory Therapies GmbH (“AResT”), a privately held biotech company focusing on the discovery and development of treatments for respiratory diseases, today announces positive final results from a Phase I clinical trial of inhaled APN01 (alunacedase alfa), a soluble recombinant version of the SARS-CoV-2 cell entry receptor ACE2.
VIENNA, Austria, April 26, 2022 (GLOBE NEWSWIRE) -- APEIRON Biologics AG announces that the annual general meeting held yesterday has approved the new structure of the group through the demerger of its preclinical and clinical development activities and the creation of a new fully separate holding company, invIOs Holding AG.
Apeiron Biologics AG, a privately held biotechnology company, announced the start of a company sponsored phase 1 trial for inhalation of APN01. The double-blind, placebo-controlled, dose-escalation study plans to enroll about 40 healthy volunteers in Austria to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of inhaled APN01.
Apeiron Biologics AG announced the start of a phase Ib clinical trial with its product candidate APN401 for the treatment of solid tumors. The principle of cell therapy with APN401 by inhibiting the immune checkpoint Cbl-b aims at the patient's own immune cells. These are modified to recognize and destroy cancer cells without being permanently genetically altered.
Apeiron Biologics AG, a privately held biotech company developing breakthrough therapies to treat cancer and respiratory conditions, announced that APN01 (alunacedase alfa) treatment showed statistically significant improvements in specific areas for severely ill Covid-19 patients.
In selecting Domainex, a UK-based biotechnology company specializing in integrated medicines research, to provide integrated lead optimization services, APEIRON Biologics, a privately held Austrian biotech company focused on cancer and respiratory therapies, will be able to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b using small-molecule drug discovery.
In selecting Domainex, a UK-based biotechnology company specializing in integrated medicines research, to provide integrated lead optimization services, APEIRON Biologics, a privately held Austrian biotech company focused on cancer and respiratory therapies, will be able to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b using small-molecule drug discovery.
Privately-held biotech company, Apeiron Biologics, has selected integrated drug discovery research partner, Domainex, to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b, it was announced in a Nov. 9, 2020 press release.
Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431
VIENNA, Sept. 24, 2020 /PRNewswire/ -- APEIRON Biologics AG today announced that first, encouraging data with its clinical drug candidate APN01 (rhsACE2) to treat severe COVID-19 were published in the peer-reviewed journal The Lancet Respiratory Medicine 1.